Brian Kennedy

ORCID: 0000-0003-3347-917X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 Clinical Research Studies
  • Long-Term Effects of COVID-19
  • Wildlife Conservation and Criminology Analyses
  • Jewish Identity and Society
  • Patient Safety and Medication Errors
  • Global Trade and Competitiveness
  • Pharmaceutical studies and practices
  • Legal Issues in South Africa
  • Mormonism, Religion, and History
  • SARS-CoV-2 detection and testing
  • Occupational Health and Safety Research
  • Jewish and Middle Eastern Studies
  • Law in Society and Culture
  • Water resources management and optimization
  • Law, logistics, and international trade
  • Corporate Law and Human Rights
  • Risk Management in Financial Firms
  • Pharmaceutical Practices and Patient Outcomes
  • Securities Regulation and Market Practices
  • Environmental law and policy

Mayo Clinic in Arizona
2024

Mayo Clinic Health System
2021-2022

Mentaal Beter
2021

Terra
2021

The Ohio State University Newark
2011

Bamlanivimab and casirivimab-imdevimab are authorized for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. We compared the outcomes patients who received these therapies identify factors associated with hospitalization other clinical outcomes.Adult monoclonal antibody from 19 November 2020 11 February 2021 were selected divided into those bamlanivimab (n = 2747) 849). The 28-day all-cause COVID-19-related hospitalizations between groups.The population...

10.1093/infdis/jiab377 article EN other-oa The Journal of Infectious Diseases 2021-07-17

The administration of spike monoclonal antibody treatment to patients with mild moderate COVID-19 is very challenging. This article summarizes essential components and processes in establishing an effective infusion program. Rapid identification a dedicated physical infrastructure was circumvent the logistical challenges caring for infectious while maintaining compliance regulations ensuring safety our personnel other patients. Our partnerships collaborations among multiple different...

10.1016/j.mayocp.2021.03.010 article EN other-oa Mayo Clinic Proceedings 2021-03-09

Abstract Objectives Since the 1970s, a plethora of tools have been introduced to support medication use process. However, automation initiatives assist pharmacists in prospectively reviewing orders are lacking. The review many medications may be protocolized and implemented an algorithmic fashion utilizing discrete data from electronic health record (EHR). This research serves as proof concept evaluate capability effectiveness prospective order (EPMOR) system compared pharmacists’ review....

10.1093/jamiaopen/ooae003 article EN cc-by-nc JAMIA Open 2024-01-04

To describe and compare the clinical outcomes of bamlanivimab-etesevimab, casirivimab-imdevimab, sotrovimab treatment mild to moderate coronavirus disease 2019 (COVID-19) during severe acute respiratory 2 (SARS-CoV-2) B.1.617.2 Delta surge. This is a retrospective study high-risk patients who received for COVID-19 between August 1, 2021, December 2021. Rates disease, hospitalization, intensive care unit admission, death were assessed. Among 10,775 or surge, 287 (2.7%) developed that led...

10.1016/j.mayocp.2022.06.015 article EN cc-by-nc-nd Mayo Clinic Proceedings 2022-06-23

In early 1951, the Israeli Knesset Library arranged to dedicate a series of American Congressional Record Senator Robert A. Taft, who “was unquestionably major factor in shaping Pre...

10.1111/j.1540-6563.2011.00305.x article EN Historian 2011-12-01

10.5235/elr.v4n2.293 article EN European Law Reports 2000-03-01

The recent Supreme Court decision in Fish and Wildlife Service v. Sierra Club presents a conflict between the public’s right to know federal agency policies agency’s interest protecting its deliberative materials from public review. claimed that was violating Freedom of Information Act by refusing provide biological opinions – required analysis potential impact regulations on endangered species marking them draft never producing final opinion would be publicly available. This article...

10.1080/10406026.2021.1981681 article EN Environmental Claims Journal 2021-09-23
Coming Soon ...